Tianchen Biological Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2020

Location

Changshu Jiangsu China

Primary Industry

Biotechnology

About

Established in 2020 and based in Suzhou, China, Tianchen Biological is a biomedical company that specializes in the research and development of differentiated macromolecular antibodies in the field of autoimmune diseases. In March 2021, the company's products LP-003 and LP-001 received clinical approval from the State Drug Administration. Dr. Niachao Sun of the company, is the founder of Tanox, USA, and Dr. Heng Liu graduated from the State University of New York with a Ph.D. in Biology. The company has cooperated with RxVision. The company also established a research and development center in Shanghai. In October 2023, it raised over CNY 100 million in series B funding from new investors Changshu Kaisheng Equity Investment Fund, Hefei Ruicheng Venture Capital Management, Oriental Fortune Capital, Shanghai Tongrui Investment Management and Shanzheng Innovation Investment. In September 2024, the firm raised approximately CNY 100 million in series B+ funding. The technology platforms developed by the company include antibody discovery platform, antibody engineering platform and process development platform. Antibody engineering platform includes the modification of recoverable antibodies, modification of CHO display platform and other functions. The pipelines of the company include LP-003, LP-001, LP-005, LP-006, and other pipelines, which can be used in ophthalmology, nephrology, hematology. The company also provides antibody testing services. The company’s revenue is generated by providing large molecule antibodies. The company will use the funding to advance clinical research of core projects in China, accelerate product launches and expand into the international market.

Current Investors

Oriental Fortune Capital, Sangel Capital, New China Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals

Website

www.longbio.com

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.